Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

BACKGROUND: Simvastatin, 20 mg, plus ezetimibe, 10 mg, daily (simvastatin plus ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown. STUDY DESIGN: Cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Mihaylova, Borislava, Schlackow, Iryna, Herrington, William, Lozano-Kühne, Jingky, Kent, Seamus, Emberson, Jonathan, Reith, Christina, Haynes, Richard, Cass, Alan, Craig, Jonathan, Gray, Alastair, Collins, Rory, Landray, Martin J., Baigent, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801501/
https://www.ncbi.nlm.nih.gov/pubmed/26597925
http://dx.doi.org/10.1053/j.ajkd.2015.09.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801501/
https://www.ncbi.nlm.nih.gov/pubmed/26597925
http://dx.doi.org/10.1053/j.ajkd.2015.09.020

Ejemplares similares